SAXAGLIPTIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H25N3O2.H2O
Molecular Weight	333.4253
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.[H][C@@]12C[C@]1([H])N([C@@H](C2)C#N)C(=O)[C@@H](N)C34CC5CC(CC(O)(C5)C3)C4

InChI

InChIKey=AFNTWHMDBNQQPX-NHKADLRUSA-N

InChI=1S/C18H25N3O2.H2O/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17;/h10-15,23H,1-7,9,20H2;1H2/t10?,11?,12-,13+,14+,15-,17?,18?;/m1./s1

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB06335
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/monograph/saxagliptin-hydrochloride.html

Saxagliptin is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor antidiabetic for the treatment of type 2 diabetes. DPP-4 inhibitors are a class of compounds that work by affecting the action of natural hormones in the body called incretins. Incretins decrease blood sugar by increasing consumption of sugar by the body, mainly through increasing insulin production in the pancreas, and by reducing production of sugar by the liver. [Bristol-Myers Squibb Press Release] DPP-4 is a membrane associated peptidase which is found in many tissues, lymphocytes and plasma. DPP-4 has two main mechanisms of action, an enzymatic function and another mechanism where DPP-4 binds adenosine deaminase, which conveys intracellular signals via dimerization when activated. Saxagliptin forms a reversible, histidine-assisted covalent bond between its nitrile group and the S630 hydroxyl oxygen on DPP-4. The inhibition of DPP-4 increases levels active of glucagon like peptide 1 (GLP-1), which inhibits glucagon production from pancreatic alpha cells and increases production of insulin from pancreatic beta cells.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dipeptidyl peptidase IV 37 Target ID: CHEMBL284 Sources: http://www.drugbank.ca/drugs/DB06335 \| https://www.ncbi.nlm.nih.gov/pubmed/18223196	Inhibitor 8297		30.3 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 259 Sources: https://www.drugs.com/monograph/saxagliptin-hydrochloride.html	Primary		Approved 8429	Onglyza Approved Use Diabetes mellitus, type 2: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (noninsulin dependent, NIDDM) as monotherapy or in combination therapy. Launch Date 2009

C_max

Value	Dose	Co-administered	Analyte	Population
24 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		SAXAGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
78 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		SAXAGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		SAXAGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		SAXAGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
10 mg 1 times / day steady, oral Highest studied dose Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19650754/ Page: table 4	unhealthy, adult n = 98 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 98 Sources: https://pubmed.ncbi.nlm.nih.gov/19650754/ Page: table 4	Disc. AE: Adverse event... AEs leading to discontinuation/dose reduction: Adverse event (5.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/19650754/ Page: table 4
2.5 mg 1 times / day steady, oral Recommended Dose: 2.5 mg, 1 times / day Route: oral Route: steady Dose: 2.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4	unhealthy, adult n = 882 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: unknown Population Size: 882 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4	Disc. AE: Lymphopenia, Rash... AEs leading to discontinuation/dose reduction: Lymphopenia (0.1%) Rash (0.2%) Blood creatinine increased (0.3%) Blood creatine phosphokinase increased (0.1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4	unhealthy, adult n = 882 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: unknown Population Size: 882 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4	Disc. AE: Lymphopenia, Rash... AEs leading to discontinuation/dose reduction: Lymphopenia (0.5%) Rash (0.3%) Blood creatine phosphokinase increased (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4

AEs

AE	Significance	Dose	Population
Adverse event	5.1% Disc. AE	10 mg 1 times / day steady, oral Highest studied dose Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19650754/ Page: table 4	unhealthy, adult n = 98 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: M+F Population Size: 98 Sources: https://pubmed.ncbi.nlm.nih.gov/19650754/ Page: table 4
Blood creatine phosphokinase increased	0.1% Disc. AE	2.5 mg 1 times / day steady, oral Recommended Dose: 2.5 mg, 1 times / day Route: oral Route: steady Dose: 2.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4	unhealthy, adult n = 882 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: unknown Population Size: 882 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4
Lymphopenia	0.1% Disc. AE	2.5 mg 1 times / day steady, oral Recommended Dose: 2.5 mg, 1 times / day Route: oral Route: steady Dose: 2.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4	unhealthy, adult n = 882 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: unknown Population Size: 882 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4
Rash	0.2% Disc. AE	2.5 mg 1 times / day steady, oral Recommended Dose: 2.5 mg, 1 times / day Route: oral Route: steady Dose: 2.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4	unhealthy, adult n = 882 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: unknown Population Size: 882 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4
Blood creatinine increased	0.3% Disc. AE	2.5 mg 1 times / day steady, oral Recommended Dose: 2.5 mg, 1 times / day Route: oral Route: steady Dose: 2.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4	unhealthy, adult n = 882 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: unknown Population Size: 882 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4
Blood creatine phosphokinase increased	0.2% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4	unhealthy, adult n = 882 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: unknown Population Size: 882 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4
Rash	0.3% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4	unhealthy, adult n = 882 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: unknown Population Size: 882 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4
Lymphopenia	0.5% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4	unhealthy, adult n = 882 Health Status: unhealthy Condition: type 2 diabetes Age Group: adult Sex: unknown Population Size: 882 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf Page: 4

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 781	inhibitor 1767 inducer 389	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2B6 810 CYP2C8 911 CYP2C19 1478 CYP2E1 882 CYP3A4/5 278 P-gp 1461 OCT2 647	CYP3A4/5 85 CYP1A2 1054 CYP2C19 991 P-gp 1537 OATP1B1 406 OATP1B3 350 OCT1 327 OCT2 355 OAT1 326 OAT3 339 PEPT1 49 PEPT2 32	CYP3A4/5 124 CYP1A2 701 CYP2B6 547 P-gp 257

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2C9 1819	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	inconclusive
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	no
CYP3A4/5 335	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf#page=17 Page: 17.0	no	no (co-administration study) Comment: administration with simvastatin did not alter PK of metformin; administration with diltiazem increased the plasma Cmax of diltiazem by 16%, AUC of diltiazem was unchagned Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf#page=17 Page: 17.0
CYP3A4/5 335	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf#page=17 Page: 17.0	no	no (co-administration study) Comment: administration with simvastatin did not alter PK of metformin; administration with diltiazem increased the plasma Cmax of diltiazem by 16%, AUC of diltiazem was unchanged; administration with ketoconazole decreased Cmax and AUC of ketoconazole by 16% and 13%, respectively; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf#page=17 Page: 17.0
OCT2 648	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf#page=16 Page: 16.0	no	no (co-administration study) Comment: administration with metformin did not alter PK of metformin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf#page=16 Page: 16.0
P-gp 1650	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	no	no (co-administration study) Comment: administered with digoxin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	no	no (co-administration study) Comment: administered with digoxin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	no	unlikely (co-administration study) Comment: no concentration and time-dependent inhibtion; administration with pioglitazone increased the plasma Cmax of glyburide by 14%, AUC was unchanged. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	no	unlikely (co-administration study) Comment: no concentration and time-dependent inhibtion; administration with glyburide increased the plasma Cmax of glyburide by 16%, AUC was unchanged. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4/5 85	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=38 Page: 38,42	major	yes (co-administration study) Comment: ketoconazole increased the Cmax for saxagliptin by 62% and the AUC by 2.5-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=38 Page: 38,42
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=38 Page: 38.0	minor
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=38 Page: 38.0	minor
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=38 Page: 38.0	minor
OAT1 326	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=40 Page: 40.0	no
OAT3 339	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=40 Page: 40.0	no
OATP1B1 406	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	no
OATP1B3 350	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	no
OCT1 327	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=40 Page: 40.0	no
OCT2 355	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=40 Page: 40.0	no
PEPT1 49	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=40 Page: 40.0	no
PEPT2 32	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=40 Page: 40.0	no
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0	yes	no (co-administration study) Comment: administration with digoxin did not alter PK of saxagliptin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_ClinPharmR_P1.pdf#page=39 Page: 39.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_PharmR_P5.pdf#page=31 Page: 31.0

Sourcing

Vendor/Aggregator	ID	URL
Achemo Scientific Limited	AC-73827	http://www.achemo.com/search/?Keyword=361442-04-8
Achemtek	0101-002229	http://www.achemtek.com/361442-04-8
Achemtek	0102-022621	http://www.achemtek.com/361442-04-8
Acorn PharmaTech	ACN-031557	http://www.acornpharmatech.com/
Adooq BioScience	Saxagliptin - BMS-477118	http://www.adooq.com/saxagliptin-bms-477118.html
Ambeed	A354223	https://www.ambeed.com/products/361442-04-8.html
Ambinter	Amb17620035	http://www.ambinter.com/reference/17620035
Aurora Fine Chemicals LLC	A24.090.433	http://online.aurorafinechemicals.com/info?ID=A24.090.433
Aurum Pharmatech LLC	Q-4418	http://www.Aurumpharmatech.com/Product/ProductDetails/Q_4418
AvaChem Scientific	2771	http://www.avachem.com/productSearch.asp?2771
BLD Pharm	BD162102	http://www.bldpharm.com/products/361442-04-8.html
BioCrick	BCC3934	http://www.biocrick.com/Saxagliptin-BCC3934.html
CSNpharm	CSN12346	https://www.csnpharm.com/products/saxagliptin.html
Chem Scene	CS-0650	http://www.chemscene.com/361442-04-8.html
ChemMol	30112400	http://www.chemmol.com/chemmol/30112400.html
ChemMol	44014170	http://www.chemmol.com/chemmol/44014170.html
Chemspace	CSSB00015193110	https://chem-space.com/CSSB00015193110
DC Chemicals	DC8875	http://www.dcchemicals.com/product_show-Saxagliptin.html
Enamine	Z2235802036	https://www.enaminestore.com/catalog/Z2235802036
LGC Standards	MM3377.01	https://www.lgcstandards.com/US/en/p/MM3377.01
Lab Network	LN01295323	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01295323
Matrix Scientific	122721	https://www.matrixscientific.com/122721.html
MedChem Express	HY-10285	https://www.medchemexpress.com/Saxagliptin.html
Parkway Scientific	WU-553	http://www.parkwayscientific.com/searchproduct.php?txt_search=WU-553
Selleck Chemicals	S1540	http://www.selleckchem.com/products/Saxagliptin(Onglyza).html
Smolecule	S639894	https://www.smolecule.com/products/s639894
THE BioTek	bt-345214	https://www.thebiotek.com/product/others/bt-345214
VladaChem	VL281619-10MG	https://www.vladachem.com/product.php?products=361442-04-8
Yuhao Chemical	CJ2102	http://www.chemyuhao.com/361442-04-8.html
eNovation Chemicals	D541352	https://www.enovationchem.com/ProductDetails.asp?ProductID=D541352
eNovation Chemicals	Y0973983	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0973983
iChemical	EBD1390	http://www.ichemical.com/products/361442-04-8.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.	2008 Apr	18223196
Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.	2009 Sep-Oct	19904014

Patents

Sample Use Guides

In Vivo Use Guide

Diabetes Mellitus Monotherapy Oral 2.5 or 5 mg once daily.1 Higher dosages (e.g., 10 mg once daily) did not provide additional benefit in clinical trials and are not recommended by manufacturer.

Route of Administration: Oral

In Vitro Use Guide

Saxagliptin inhibited rat plasma DPP-IV activity in vitro with an IC(50) value of 2.00 nmol/l

Name

Type

Language

SAXAGLIPTIN

Official Name

English

SAXAGLIPTIN MONOHYDRATE

Preferred Name

English

BMS-477118-11

Code

English

SAXAGLIPTIN HYDRATE

Common Name

English

SAXAGLIPTIN [USAN]

Common Name

English

(1S,3S,5S)-2-((2S)-AMINO(3-HYDROXYTRICYCLO(3.3.1.1(SUP 3,7))DEC-1-YL)ACETYL)2-AZABICYCLO(3.1.0)HEXANE-3-CARBONITRILE MONOHYDRATE

Systematic Name

English

QTERNMET COMPONENT SAXAGLIPTIN

Brand Name

English

SAXAGLIPTIN MONOHYDRATE [MI]

Common Name

English

SAXAGLIPTIN [MART.]

Common Name

English

Saxagliptin monohydrate [WHO-DD]

Common Name

English

NSC-760407

Code

English

SAXAGLIPTIN [VANDF]

Common Name

English

SAXAGLIPTIN HYDRATE [JAN]

Common Name

English

SAXAGLIPTIN COMPONENT OF QTERNMET

Brand Name

English

2-AZABICYCLO(3.1.0)HEXANE-3-CARBONITRILE, 2-((2S)-2-AMINO-2-(3-HYDROXYTRICYCLO(3.3.1.1(SUP 3,7))DEC-1-YL)ACETYL)-, HYDRATE (1:1), (1S,3S,5S)-

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C98086